Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders

Current Drug Targets

Volumn 13, Issue 6, 2012, Pages 842-862

  Antonioli, Luca ^a   Colucci, Rocchina ^a   la Motta, Concettina ^a   Tuccori, Marco ^a   Awwad, Oriana ^a   da Settimo, Federico ^a   Blandizzi, Corrado ^a   Fornai, Matteo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adenosine; Adenosine deaminase; Adenosine deaminase inhibitors; Dipeptidyl peptidase IV; Immune cell cancer; Immune system; Inflammation; Neurodegenerative diseases

Indexed keywords

1 (1 HYDROXY 4 PHENYLBUTAN 2 YL) 1H IMIDAZOLE 4 CARBOXAMIDE; 1 (2 HYDROXY 1 (2 (1 NAPHTHYL)ETHYL)PROPYL) 1H IMIDAZOLE 4 CARBOXAMIDE; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; COFORMYCIN; DIPEPTIDYL PEPTIDASE IV; FR 234938; PENTOSTATIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; B LYMPHOCYTE; BINDING AFFINITY; BRAIN TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; CYTOTOXICITY; DENDRITIC CELL; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; MACROPHAGE; MOLECULAR PATHOLOGY; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; NEPHROTOXICITY; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; PARKINSON DISEASE; PROLYMPHOCYTIC LEUKEMIA; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE;

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; HUMANS; IMMUNE SYSTEM; INFLAMMATION; RECEPTORS, PURINERGIC P1;

EID: 84860800094     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800564095     Document Type: Review

References (236)

1. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852.
2. Rodríguez-Molinero A, López-Diéguez M, Banegas JR. Tissue homeostasis and cancer. Med Hypotheses 2007; 68: 1333-1341.
3. Sitkovsky MV, Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 2005; 26: 299-304.
4. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-39.
5. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007; 14: 1315-1323.
6. Antonioli L, Fornai M, Colucci R, et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther 2008a; 120: 233-253.
7. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008; 117: 123-140.
8. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 364-374.
9. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011; 63: 1-34.
10. Volonté C, D'Ambrosi N. Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J 2009; 276: 318-329.
11. Antonioli L, Fornai M, Colucci R, et al. Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. Inflamm Bowel Dis 2008b; 14: 566-574.
12. Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 2003; 5: 515-526.
13. Eltzschig HK, Faigle M, Knapp S, et al. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood 2006; 108: 1602-1610.
14. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004; 104: 3986-3992.
15. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783: 673-694.
16. Van Linden A, Eltzschig HK. Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin Biol Ther 2007; 7: 1437-1447.
17. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci 2003; 24: 66-70.
18. Banerjee SK, Young HW, Barczak A, Erle DJ, Blackburn MR. Abnormal alveolar development associated with elevated adenine nucleosides. Am J Respir Cell Mol Biol 2004; 30: 38-50.
19. Németh ZH, Csóka B, Wilmanski J, et al. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol 2006; 176: 5616-5626.
20. Hashikawa T, Hooker SW, Maj JG, et al. Regulation of adenosine receptor engagement by ecto-adenosine deaminase. FASEB J 2004; 18: 131-133.
21. Hashikawa T, Takedachi M, Terakura M, et al. Activation of adenosine receptor on gingival fibroblasts. J Dent Res 2006; 85: 739-744.
22. Lasley RD, Mentzer RM. Myocardial protection: the adenosine story Drug Develop Res 1996; 39: 314-318.
23. Cristalli G, Costanzi S, Lambertucci C, et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev 2001; 21: 105-128.
24. Y. A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors. Leuk Lymphoma 2001; 42: 953-962.
25. Sauter C, Lamanna N, Weiss MA. Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol 2008; 4: 1217-1222.
26. Hirschhorn R, Ratech H. Isozymes of adenosine deaminase. Isozymes Curr Top Biol Med Res 1980; 4: 131-157.
27. Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem 1992; 38: 1322-1326.
28. Maier SA, Galellis JR, McDermid HE. Phylogenetic analysis reveals a novel protein family closely related to adenosine deaminase. J Mol Evol 2005; 61: 776-794.
29. Zavialov AV, Engström A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 2005; 391: 51-57.
30. Wilson DK, Rudolph FB, Quiocho FA. Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 1991; 252: 1278-1284.
31. Sharff AJ, Wilson DK, Chang Z, Quiocho FA. Refined 2.5 A structure of murine adenosine deaminase at pH 6.0. J Mol Biol 1992; 226: 917-921.
32. 2+ on the structure and stability of murine adenosine deaminase. J Phys Chem B 2010; 114: 16156-16165.
33. Kinoshita T, Ataka M, Warizaya M, Neya M, Fujii T. Improving quality and harvest period of protein crystals for structure-based drug design: effects of a gel and a magnetic field on bovine adenosine deaminase crystals. Acta Crystallogr D Biol Crystallogr 2003a; 59: 1333-1335.
34. Kinoshita T, Nishio N, Nakanishi I, Sato A, Fujii T. Structure of bovine adenosine deaminase complexed with 6-hydroxy-1,6-dihydropurine riboside. Acta Crystallogr D Biol Crystallogr 2003b; 59: 299-303.
35. Kinoshita T, Nakanishi I, Terasaka T, et al. Structural basis of compound recognition by adenosine deaminase. Biochemistry 2005; 44: 10562-10569.
36. Kinoshita T, Tada T, Nakanishi I. Conformational change of adenosine deaminase during ligand-exchange in a crystal. Biochem Biophys Res Commun 2008; 373: 53-57.
37. Zavialov AV, Yu X, Spillmann D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem 2010; 285: 12367-12377.
38. Rawlings ND, Tolle DP, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 2004;32:D160-D164.
39. Akedo H, Nishihara H, Shinkae K, Komatsu K. Adenosine deaminases of two different molecular sizes in human tissues. Biochim Biophys Acta. 1970; 212: 189-191.
40. Akedo H, Nishihara H, Shinkai K, Komatsu K, Ishikawa S. Multiple forms of human adenosine deaminase. I. Purification and characterization of two molecular species. Biochim Biophys Acta 1972; 276: 257-271.
41. Edwards YH, Hopkinson DA, Harris H. Adenosine deaminase isozymes in human tissues. Ann Hum Genet 1971; 35: 207-219.
42. Van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. J Biol Chem 1976; 251: 5448-5456.
43. Schrader WP, Stacy AR. Purification and subunit structure of adenosine deaminase from human kidney. J Biol Chem 1977; 252: 6409-6415.
44. Bielat K, Tritsch GL. Ecto-enzyme activity of human erythrocyte adenosine deaminase. Mol Cell Biochem 1989; 86: 135-142.
45. Aran JM, Colomer D, Matutes E, Vives-Corrons JL, Franco R. Presence of adenosine deaminase on the surface of mononuclear blood cells: immunochemical localization using light and electron microscopy. J Histochem Cytochem 1991; 39: 1001-1008.
46. Daddona PE, Kelley WN. Human adenosine deaminase. Stoichiometry of the adenosine deaminase-binding protein complex. Biochim Biophys Acta 1979; 580: 302-311.
47. Dinjens WN, van der Boon J, ten Kate J, et al. Cell surface adenosine deaminase (ADA) and its complexing protein (ADCP) in human T-lymphoid cells. Adv Exp Med Biol 1986; 195: 407-414.
48. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261: 466-469.
49. Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994; 40: 331-338.
50. Misumi Y, Hayashi Y, Arakawa F, Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta 1992; 1131: 333-336.
51. Yaron A, Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 1993; 28: 31-81.
52. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9-24.
53. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009; 16: 2943-2951.
54. Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003; 100: 5063-5068.
55. Schrader WP, West CA, Miczek AD, Norton EK. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. J Biol Chem 1990; 265: 19312-19318.
56. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998; 161: 55-70.
57. Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998; 161: 27-42.
58. Dong RP, Kameoka J, Hegen M, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996; 156: 1349-1355.
59. Dong RP, Tachibana K, Hegen M, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997; 159: 6070-6.
60. Martinez-Navio JM, Casanova V, Pacheco R, et al. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol 2011; 89: 127-136.
61. De Meester I, Vanham G, Kestens L, et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994; 24: 566-570.
62. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem 2004; 279: 43330-43335.
63. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 1996; 380: 219-223.
64. Herrera C, Casadó V, Ciruela F, et al. Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol 2001; 59: 127-134.
65. Franco R, Casadó V, Ciruela F, et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 1997; 52: 283-294.
66. Agarwal RP. Inhibitors of adenosine deaminase. Pharmacol Ther 1982; 17: 399-429.
67. Franco R, Centelles JJ. Adenosine deaminase inhibitors as therapeutic agents. Drugs Today 1989, 25, 155-170.
68. Vittori S, Camaioni E, Costanzi S, Volpini R, Lupidi G, Cristalli G. Structure-activity relationships of adenosine deaminase inhibitors. Nucleosides Nucleotides Nucleic Acids 1999; 18: 741-742.
69. Terasaka T. Non-nucleoside adenosine deaminase inhibitors: 2000-2004. Expert Opin Therap Pat 2005; 15, 817-828.
70. Sawa T, Fukagawa Y, Homma I, Takeuchi T, Umezawa H. Mode of inhibition of coformycin on adenosine deaminase. J Antibiot (Tokyo) 1967; 20: 227-231.
71. Nakamura H, Koyama G, Iitaka Y, Ono M, Yagiawa N. Structure of coformycin, an unusual nucleoside of microbial origin. J Am Chem Soc 1974; 96: 4327-4328.
72. Woo PWK, Dion HW, Lange SM, Dahl LF, Durham LJ. A novel adenosine and ara-A deaminase Inhibitor, (R)-3-(2-deoxy-â-D- erythropentofuranosyl)-3,6,7,8-tetrahydroimidazo-[4,5-d]diazepin-8-ol. J Heterocycl Chem 1974; 11: 641-643.
73. Nakamura H, Koyama G, Umezawa H, Iitaka Y. The crystal and molecular structure of coformycin. Acta Crystallogr 1976; B32: 1206-1212.
74. Agarwal RP, Spector T, Parks RE Jr. Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol 1977; 26: 359-367.
75. Agarwal RP, Cha S, Crabtree GW, Parks RE. Coformycin and deoxycoformycin: Tight-binding inhibitors of adenosine deaminase. Chemistry and Biology of Nucleosides and Nucleotides; Academic Press: New York, 1978; pp 159-197.
76. Frick L, Wolfenden R, Smal E, Baker DC. Transition-state stabilization by adenosine deaminase: structural studies of its inhibitory complex with deoxycoformycin. Biochemistry 1986; 25: 1616-1621.
77. Kati WM, Wolfenden R. Contribution of a single hydroxyl group to transition-state discrimination by adenosine deaminase: evidence for an entropy trap mechanism. Biochemistry 1989; 28: 7919-7927.
78. Kurz LC, Moix L, Riley MC, Frieden C. The rate of formation of transition-state analogues in the active site of adenosine deaminase is encounter-controlled: implications for the mechanism. Biochemistry 1992; 31: 39-48.
79. Schramm VL, Baker DC. Spontaneous epimerization of (S)-deoxycoformycin and interaction of (R)-deoxycoformycin, (S)-deoxycoformycin, and 8-ketodeoxycoformycin with adenosine deaminase. Biochemistry 1985; 24: 641-646.
80. Smyth JF, Poplack DG, Holiman BJ, Leventhal BG, Yarbro G. Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. J Clin Invest 1978; 62: 710-712.
81. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med 1988; 108: 733-743.
82. Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009; 109: 2880-2893.
83. Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 1991; 64: 903-6.
84. Kane BJ, Kuhn JG, Roush MK. Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 1992; 26: 939-947.
85. AS. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases. Haematologia (Budap) 1996; 27: 55-84.
86. Cabanillas F. Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park) 2000; 14: 13-15.
87. Ho AD, Hensel M. Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol 2006; 2: 169-183.
88. Juliusson G, Liliemark J. Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemia. Hematol Oncol Clin North Am 2006; 20: 1087-1097.
89. Major PP, Agarwal RP, Kufe DW. Deoxycoformycin: neurological toxicity. Cancer Chemother Pharmacol 1981; 5: 193-196.
90. Brogden RN, Sorkin EM. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993; 46: 652-77.
91. Reayi A, Hosmane RS. Inhibition of adenosine deaminase by novel 5:7 fused heterocycles containing the imidazo[4,5-e][1,2,4]triazepine ring system: a structure-activity relationship study. J Med Chem 2004; 47: 1044-1050.
92. Omura S, Imamura N, Kuga H, et al. Adechlorin, a new adenosine deaminase inhibitor containing chlorine production, isolation and properties. J Antibiot (Tokyo) 1985; 38: 1008-1015.
93. Omura S, Ishikawa H, Kuga H, et al. Adecypenol, a unique adenosine deaminase inhibitor containing homopurine and cyclopentene rings. Taxonomy, production and enzyme inhibition. J Antibiot(Tokyo) 1986; 39: 1219-1224.
94. Marrone TJ, Straatsma TP, Briggs JM, Wilson DK, Quiocho FA, McCammon JA. Theoretical study of inhibition of adenosine deaminase by (8R)-coformycin and(8R)-deoxycoformycin. J Med Chem 1996; 39: 277-284.
95. Wang Z, Quiocho FA. Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity. Biochemistry 1998; 37: 8314-8324.
96. Schaeffer HJ, Schwender CF. Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J Med Chem 1974; 17: 6-8.
97. Bessodes M, Bastian G, Abushanab E, et al. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem Pharmacol 1982; 31: 879-882.
98. Barankiewicz J, Danks AM, Abushanab E, et al. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J Pharmacol Exp Ther 1997; 283: 1230-1238.
99. Vargeese C, Sarma MS, Pragnacharyulu PV, Abushanab E, Li SY, Stoeckler JD. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine. J Med Chem 1994; 37: 3844-3849.
100. Curtis MA, Varkhedkar V, Pragnacharyulu PV, Abushanab E. Adenosine deaminase inhibitors. Synthesis and biological evaluation of aralkyladenines (ARADS). Bioorg Med Chem Lett 1998; 8: 1639-1642.
101. Pragnacharyulu PV, Varkhedkar V, Curtis MA, Chang IF, Abushanab E. Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R-nonyl)adenine[(+)-EHNA]. J Med Chem 2000; 43: 4694-4700.
102. Harriman GC, Poirot AF, Abushanab E, Midgett RM, Stoeckler JD. Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine. J Med Chem 1992; 35: 4180-4184.
103. Brakta M, Murthy D, Ellis L, Phadtare S. 9-[(Hydroxymethyl)phenyl]adenines: new aryladenine substrates of adenosine deaminase. Bioorg Med Chem Lett 2002; 12: 1489-1492.
104. Harriman GC, Abushanab E, Stoeckler JD. Adenosine deaminase inhibitors. Synthesis and biological evaluation of 4-amino-1-(2(S)- hydroxy-3(R)-nonyl)-1H-imidazo[4,5-c]pyridine (3-deaza-(+)- EHNA) and certain C1' derivatives. J Med Chem 1994; 37: 305-308.
105. Lupidi G, Riva F, Cristalli G, Grifantini M. Inhibition of adenosine deaminase by deaza derivatives of adenosine and purine riboside. Ital J Biochem 1982; 31: 396-403.
106. Antonini I, Cristalli G, Franchetti P, et al. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem 1984;27: 274-278.
107. Lupidi G, Cristalli G, Marmocchi F, Riva F, Grifantini M. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA. J Enzyme Inhib 1985; 1: 67-75.
108. Cristalli G, Franchetti P, Grifantini M, et al. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem 1988; 31: 390-393.
109. Cristalli G, Eleuteri A, Franchetti P, Grifantini M, Vittori S, Lupidi G. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3 nonyl)adenine. J Med Chem 1991; 34: 1187-1192.
110. Cristalli G, Eleuteri A, Vittori S, Volpini R, Campioni E, Lupidi G. Adenosine deaminase inhibitors - structure-activity relatioships in 1-deazaadenosine and eritro-9-(2-hydroxy-3-nonyl)adenine analogues. Drug Dev Res 1993; 28: 253-258.
111. Cristalli G, Eleuteri A, Volpini R, Vittori S, Camaioni E, Lupidi G. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles. J Med Chem 1994; 37: 201-205.
112. Volpini R, Camaioni E, Lupidi G, Vittori S, Cristalli G. Adenosine deaminase inhibitors: synthesis, diastereoisomeric resolution and biological activity of 1-(2-hydroxy-3-nonyl)-1,2,4-triazole-3-carboxamide. Farmaco 1997; 52: 429-433.
113. Costanzi S, Lambertucci C, Volpini R, Vittori S, Lupidi G, Cristalli G. 3'-deoxyribofuranose derivatives of 1-deaza and 3-deaza-adenosine and their activity as adenosine deaminase inhibitors. Nucleosides Nucleotides Nucleic Acids 2001; 20: 1037-1041.
114. Da Settimo F, Primofiore G, La Motta C, et al. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4 d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies. J Med Chem 2005; 48: 5162-5174.
115. Antonioli L, Fornai M, Colucci R, et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther 2007; 322: 435-442.
116. La Motta C, Sartini S, Mugnaini L, et al. M. Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. J Med Chem 2009; 52: 1681-1692.
117. Antonioli L, Fornai M, Colucci R, et al. The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. J Pharmacol Exp Ther 2010a; 335: 434-442.
118. Wilson DK, Quiocho FA. A pre-transition-state mimic of an enzyme: X-ray structure of adenosine deaminase with bound 1-deazaadenosine and zinc-activated water. Biochemistry 1993; 32: 1689-1694.
119. Terasaka T, Nakanishi I, Nakamura K, et al. Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors. Bioorg Med Chem Lett 2003; 13: 1115-1118.
120. Terasaka T, Kinoshita T, Kuno M, Nakanishi I. A highly potent non nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization. J Am Chem Soc 2004; 126: 34-35.
121. Terasaka T, Kinoshita T, Kuno M, Seki N, Tanaka K, Nakanishi I. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. J Med Chem 2004; 47: 3730-43.
122. Terasaka T, Okumura H, Tsuji K, et al. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. J Med Chem 2004; 47: 2728-2731.
123. Terasaka T, Tsuji K, Kato T, et al. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism. J Med Chem 2005; 48: 4750-4753.
124. Kuno M, Seki N, Tsujimoto S, et al. Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. Eur J Pharmacol 2006; 534: 241-249.
125. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067-1069.
126. Ackeret C, Llüss HJ, Hitzig WH. Hereditary severe combined immunodeficiency and adenosine deaminase deficiency. Pediatr Res 1976; 10: 67-70.
127. Benke PJ, Dittmar D. Purine dysfunction in cells from patients with adenosine deaminase deficiency. Pediatr Res 1976; 10: 642-646.
128. Hirschhorn R. Adenosine deaminase deficiency and immunodeficiencies. Fed Proc 1977; 36: 2166-2170.
129. Aldrich MB, Blackburn MR, Kellems RE. The importance of adenosine deaminase for lymphocyte development and function. Biochem Biophys Res Commun 2000; 272: 311-315.
130. Franco R, Pacheco R, Gatell JM, Gallart T, Lluis C. Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 2007; 27: 495-509.
131. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005; 4: 281-286.
132. Adamson R. Role of macrophages in normal wound healing: an overview. J Wound Care 2009; 18: 349-351.
133. Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun 2009; 33: 222-230.
134. Laskin DL. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol 2009; 22: 1376-85.
135. Hunter M, Wang Y, Eubank T, Baran C, Nana-Sinkam P, Marsh C. Survival of monocytes and macrophages and their role in health and disease. Front Biosci 2009; 14: 4079-4102.
136. Haskó G, Szabó C, Németh ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157: 4634-4640.
137. Németh ZH, Lutz CS, Csóka B, et al. Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol 2005; 175: 8260-8270.
138. Csóka B, Németh ZH, Virág L, et al. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 2007; 110: 2685-2695.
139. Fischer D, Van der Weyden MB, Snyderman R, Kelley WN. A role for adenosine deaminase in human monocyte maturation. J Clin Invest 1976; 58: 399-407.
140. Soberman RJ, Karnovsky ML. Metabolism of purines in macrophages. Effect of functional state of the cells. J Exp Med 1980; 152: 241-246.
141. Tritsch GL, Niswander PW. Adenosine deaminase activity and superoxide formation during phagocytosis and membrane perturbation of macrophages. Immunol Commun 1981; 10: 1-8.
142. Yagawa K, Okamura J. Role of adenosine deaminase in activation of macrophages.Infect Immun 1981; 32: 394-397.
143. Tritsch GL, Niswander PW. Purine catabolism as a source of superoxide in macrophages. Ann N Y Acad Sci 1985; 451: 279-290.
144. Conlon BA, Law WR. Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol 2004; 138: 14-20.
145. Burger D, Dayer JM. The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res 2002; 4: S169-S176.
146. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005;35:25-30.
147. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005;86:1-41.
148. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest 2001;108:131-141
149. Daddona PE. Human adenosine deaminase. Properties and turnover in cultured T and B lymphoblasts. J Biol Chem 1981; 256: 12496-12501.
150. Chechik BE, Schrader WP, Fernandes B, Sengupta S, Gelfand EW. Association of adenosine deaminase with differentiation of normal and leukemic T and B lymphocytes. Ann N Y Acad Sci 1985; 451:169-179.
151. Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RE. Impaired germinal center maturation in adenosine deaminase deficiency. J Immunol 2003;171:5562-5570
152. Freire-Moar JM, Rodriguez D, Rodriguez-Segade S, Freire M. The distribution of adenosine deaminase, purine nucleotide phosphorylase and 5'-nucleotidase in subpopulations of thymocytes, bone marrow cells and other lymphoid organs in mice. Int J Biochem 1984; 16: 225-229.
153. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 1998;273:5093-5100.
154. Németh ZH, Bleich D, Csóka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007;21:2379-2388.
155. Csóka B, Himer L, Selmeczy Z, et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 2008;22:3491-3499.
156. Martín M, Huguet J, Centelles JJ, Franco R. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995; 155: 4630-4643.
157. Dong RP, Morimoto C. Role of CD26 for CD4 memory T cell function and activation. Hum Cell 1996; 9: 153-162.
158. Cone RE, Cochrane R, Lingenheld EG, Clark RB. Elevation of intracellular cyclic AMP induces an anergic-like state in Th1 clones. Cell Immunol 1996; 173: 246-251.
159. Ishii T, Ohnuma K, Murakami A, et al. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001; 98: 12138-12143.
160. Cordero OJ, Salgado FJ, Fernández-Alonso CM, et al. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. J Leukoc Biol 2001; 70: 920-930.
161. Pacheco R, Martinez-Navio JM, Lejeune M, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 2005; 102: 9583-9588.
162. Müller I, Munder M, Kropf P, Hänsch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol 2009; 30: 522-530.
163. Kobayashi SD, Voyich JM, Burlak C, DeLeo FR. Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz) 2005; 53: 505-517.
164. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 1160-1177.
165. van Waeg G, Van den Berghe G. Purine catabolism in polymorphonuclear neutrophils. Phorbol myristate acetate-induced accumulation of adenosine owing to inactivation of extracellularly released adenosine deaminase. J Clin Invest 1991; 87: 305-312.
166. Kälvegren H, Fridfeldt J, Bengtsson T. The role of plasma adenosine deaminase in chemoattractant-stimulated oxygen radical production in neutrophils. Eur J Cell Biol 2010; 89: 462-467.
167. Ferlazzo G, Münz C. Dendritic cell interactions with NK cells from different tissues. J Clin Immunol 2009;29:265-273.
168. Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest 2009; 119: 2441-2450.
169. Desrosiers MD, Cembrola KM, Fakir MJ, et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol 2007; 179: 1884-1892.
170. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55: 395-417.
171. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001; 99: 308-319.
172. Fozard JR, Hannon JP. Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther 1999; 12: 111-114.
173. Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 2009; 30: 528-535.
174. Wilson CN, Nadeem A, Spina D, Brown R, Page CP, Mustafa SJ. Adenosine receptors and asthma. Handb Exp Pharmacol 2009; 193: 329-362.
175. Blackburn MR, Volmer JB, Thrasher JL, et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 2000; 192: 159-170.
176. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR. Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol 2001; 167: 4676-4685.
177. Zhong H, Chunn JL, Volmer JB, Fozard JR, Blackburn MR. Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice. J Pharmacol Exp Ther 2001; 298: 433-440
178. Fozard JR. The case for a role for adenosine in asthma: almost convincing? Curr Opin Pharmacol 2003; 3: 264-269.
179. Banerjee SK, Young HW, Volmer JB, Blackburn MR. Gene expression profiling in inflammatory airway disease associated with elevated adenosine. Am J Physiol Lung Cell Mol Physiol 2002; 282: L169-L182.
180. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 2005; 115: 35-43.
181. Mohsenin A, Mi T, Xia Y, Kellems RE, Chen JF, Blackburn MR. Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice. Am J Physiol Lung Cell Mol Physiol 2007; 293: L753-L761.
182. Zhou Y, Mohsenin A, Morschl E, et al. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol 2009; 182: 8037-8046.
183. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376: 1094-1108.
184. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704-712.
185. Appelboom T, Mandelbaum I, Vertongen F. Purine enzyme levels in rheumatoid arthritis. J Rheumatol 1985; 12: 1075-1078.
186. Yuksel H, Akoǧlu TF. Serum and synovial fluid adenosine deaminase activity in patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 1988; 47: 492-495.
187. Pettersson T, Klockars M, Weber TH, von Essen R. Adenosine deaminase activity in joint effusions. Scand J Rheumatol 1988; 17: 365-369.
188. Iwaki-Egawa S, Watanabe Y, Matsuno H. Correlations between matrix metalloproteinase-9 and adenosine deaminase isozymes in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 2001;28: 485-489.
189. van Ede AE, Laan RF, De Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2002; 61: 1060-1064.
190. Szabó C, Scott GS, Virág L, et al. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-387.
191. Sari RA, Taysi S, Yilmaz O, Bakan N. Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol. 2003; 21: 87-90.
192. Sebastiani GD, Bottini N, Greco E, et al. A study of Adenosine-Deaminase genetic polymorphism in rheumatoid arthritis. Int J Immunopathol Pharmacol 2010; 23: 791-795.
193. Sharma S, Das M, Kumar A, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 2009; 19: 823-828.
194. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res 2007; 149: 173-186.
195. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640.
196. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7: 759-770.
197. Al-Awadi FM, Khan I. Studies on purine enzymes in experimental colitis. Mol Cell Biochem 1999; 194: 17-22.
198. Al-Awadi FM, Khan I. Blood purine and energy status in rats with colitis. Dig Dis Sci 2001; 46: 443-448.
199. -/- colitis. Inflamm Bowel Dis 2008; 14: 880-887.
200. Maor I, Rainis T, Lanir A, Lavy A. Adenosine deaminase activity in patients with Crohn's disease: distinction between active and non active disease. Eur J Gastroenterol Hepatol 2011; 23: 598-602
201. Neunlist M, Aubert P, Toquet C, et al. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut 2003; 52: 84-90.
202. Wells RW, Blennerhassett MG. Persistent and selective effects of inflammation on smooth muscle cell contractility in rat colitis. Pflugers Arch 2004; 448: 515-524.
203. Mazzone A, Farrugia G. Evolving concepts in the cellular control of gastrointestinal motility: neurogastroenterology and enteric sciences. Gastroenterol Clin North Am. 2007; 36: 499-513
204. Duarte-Araújo M, Nascimento C, Alexandrina Timóteo M, Magalhães-Cardoso T, Correia-de-Sá P. Dual effects of adenosine on acetylcholine release from myenteric motoneurons are mediated by junctional facilitatory A(2A) and extrajunctional inhibitory A(1) receptors. Br J Pharmacol 2004; 141: 925-934.
205. Zizzo MG, Mulè F, Serio R. Inhibitory responses to exogenous adenosine in murine proximal and distal colon. Br J Pharmacol 2006; 148: 956-963.
206. Antonioli L, Fornai M, Colucci R, Ghisu N, Blandizzi C, Del Tacca M. A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. Inflamm Bowel Dis 2006; 12: 117-122.
207. De Man JG, Seerden TC, De Winter BY, Van Marck EA, Herman AG, Pelckmans PA. Alteration of the purinergic modulation of enteric neurotransmission in the mouse ileum during chronic intestinal inflammation. Br J Pharmacol 2003; 139: 172-184.
208. Antonioli L, Fornai M, Colucci R, et al. Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. Br J Pharmacol 2010b; 161: 856-871.
209. Antonioli L, Fornai M, Colucci R, et al. Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. Eur J Pharmacol 2011; 650: 639-649.
210. Antonioli L, Fornai M, Colucci R, Tuccori M, Blandizzi C. A holistic view of adenosine pathways in the control of intestinal neuromuscular functions: the enteric purinome concept. Br J Pharmacol 2011b. doi: 10.1111/j.1476-5381.2011.01529.x.
211. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
212. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163: 316-321.
213. Van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43.
214. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
215. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78.
216. Von Muller L, Klemm A, Durmus N, et al. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis 2007; 196: 1288-1295.
217. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300: 413-422.
218. Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010; 2010: 642462.
219. Haskó G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008; 83: 447-455.
220. Tofovic SP, Zacharia L, Carcillo JA, Jackson EK. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. Shock 2001; 16: 196-202.
221. Adanin S, Yalovetskiy IV, Nardulli BA, Sam AD 2nd, Jonjev ZS, Law WR. Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1324-R1332.
222. Cohen ES, Law WR, Easington CR, et al. Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am J Respir Crit Care Med 2002; 166: 16-20.
223. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-R595.
224. Law WR. Adenosine receptors in the response to sepsis: what do receptor-specific knockouts tell us? Am J Physiol Regul Integr Comp Physiol 2006; 291: R957-R958.
225. Kayhan N, Funke B, Conzelmann LO, et al. The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation. Crit Care 2008; 12: R125.
226. Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011; 71: 35-48.
227. Gomes CV, Kaster MP, Tomé AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 2011; 1808: 1380-1399.
228. Volonté C, Apolloni S, Carrì MT, D'Ambrosi N. ALS: focus on purinergic signalling. Pharmacol Ther 2011; 132: 111-122.
229. Chiba S, Matsumoto H, Saitoh M, Kasahara M, Matsuya M, Kashiwagi M. A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease. J Neurol Sci 1995; 132: 170-173.
230. Thompson LF, Vaughn JG, Laurent AB, Blackburn MR, Van De Wiele CJ. Mechanisms of apoptosis in developing thymocytes as revealed by adenosine deaminase-deficient fetal thymic organ cultures. Biochem Pharmacol 2003; 66:1595-1599.
231. Grever MR, Doan CA, Kraut EH. Pentostatin in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol 2003; 16: 91-99.
232. Riscoe MK, Brouns MC, Fitchen JH. Purine metabolism as a target for leukemia chemotherapy. Blood Rev 1989; 3: 162-173.
233. Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2' deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406-417.
234. Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196-1201.
235. Dillman RO. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev Anticancer Ther 2004; 4: 27-36.
236. Ho AD, Hensel M. Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin Hematol 2006; 43: S2-S10.